文献速递临床试验与 GCP流行病学与生物统计

马拉维农村儿童铁或复合微量营养素粉补充联合疟疾化学预防的随机临床试验

Iron or Multiple Micronutrient Powder Supplements With Malaria Chemoprevention in Rural Malawian Children: The IRMA Randomized Clinical Trial.
PubMed 文献 · JAMA · 2026-01-01

该随机临床试验在马拉维疟疾流行区纳入2168名6月龄婴儿,比较铁糖浆、含铁微量营养素粉分别联合疟疾化学预防与单用疟疾化学预防或安慰剂的效应;6个月干预后,两种铁干预均未改善认知评分,未增加疟疾风险,单用疟疾化学预防降低疟疾发病率。

要点

  • 6个月铁干预未改善1岁及18月龄Bayley-III认知评分。
  • 铁干预提高铁蛋白浓度但未降低贫血患病率。
  • 铁干预未增加疟疾风险,单用疟疾化学预防降低疟疾发病率。

核心结论

  • 两种为期6个月的普遍性铁干预联合疟疾化学预防未改善马拉维儿童的认知结局。

研究设计与样本

  • 随机临床试验在马拉维南部4个中心纳入2168名6月龄婴儿,平均年龄5.7个月,49%为女性,71%患贫血。
  • 婴儿随机分为铁糖浆联合疟疾化学预防组(n=542)、含铁微量营养素粉联合疟疾化学预防组(n=543)、单用疟疾化学预防组(n=541)或单用安慰剂组(n=542),干预6个月。
  • 主要结局为干预结束时Bayley-III认知量表复合评分,次要结局包括语言量表、运动量表复合评分、贫血患病率及血红蛋白和铁蛋白浓度,在1岁和18月龄时测量。

主要发现

  • 与单用疟疾化学预防相比,铁糖浆联合疟疾化学预防组的Bayley-III认知量表复合评分无组间差异(均数差-0.52,95%CI -2.52至1.48)。
  • 与单用疟疾化学预防相比,含铁微量营养素粉联合疟疾化学预防组的Bayley-III认知量表复合评分无组间差异(均数差-0.85,95%CI -2.80至1.09)。
  • 与单用安慰剂相比,单用疟疾化学预防组的Bayley-III认知量表复合评分无组间差异(均数差1.62,95%CI -0.31至3.55)。
  • 两种铁干预均提高铁蛋白浓度,但与单用疟疾化学预防相比均未降低贫血患病率。
  • 与单用疟疾化学预防相比,两种铁干预均未增加疟疾风险;与单用安慰剂相比,单用疟疾化学预防降低疟疾发病率。

临床怎么用

  • 在疟疾流行区,不应仅期望通过6个月铁干预来改善婴儿认知结局。
  • 铁干预联合疟疾化学预防未增加疟疾风险,但未降低贫血患病率。
  • 疟疾化学预防可降低疟疾发病率,应继续作为疟疾流行区的预防措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The World Health Organization recommends universal preventive iron interventions for young children in anemia-prevalent areas to alleviate the effects of anemia on child neurodevelopment and other outcomes. However, the functional benefits have not been confirmed in randomized clinical trials and there are concerns that iron interventions may increase infection risk. OBJECTIVE: To determine whether universal iron interventions administered with malaria chemoprevention improve child functional outcomes and are safe regarding infection risk. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial enrolled 6-month-old infants at 4 centers in southern Malawi, which is a rural, malaria-endemic setting. Enrollment occurred between April 2020 and October 2021. The final assessment was completed in October 2022. INTERVENTIONS: Six months of (1) iron syrup and malaria chemoprevention (n = 542), (2) iron-containing micronutrient powders and malaria chemoprevention (n = 543), (3) malaria chemoprevention alone (n = 541), or (4) placebo alone (n = 542). Children were assessed after the 6-month intervention period and after 6-month follow-up. MAIN OUTCOMES AND MEASURES: The primary outcome was the Cognitive Scale composite score at the end of the intervention period using the Bayley Scales of Infant and Toddler Development-Third Edition (Bayley-III). The secondary outcomes included Bayley-III Language Scale and Motor Scale composite scores, anemia prevalence, and concentrations of hemoglobin and ferritin. The primary and secondary outcomes were measured when children were 1 year of age and when they were 18 months of age. The safety outcomes included incidence of infection (including malaria). RESULTS: A total of 2168 infants (mean age, 5.7 months; 49% were female; and 71% had anemia) were recruited to participate. Compared with malaria chemoprevention alone, there was no between-group difference in the Bayley-III Cognitive Scale composite score for iron syrup and malaria chemoprevention (mean difference [MD], -0.52 [95% CI, -2.52 to 1.48]). Compared with malaria chemoprevention alone, there was no between-group difference in the Bayley-III Cognitive Scale composite score for iron-containing micronutrient powders and malaria chemoprevention (MD, -0.85 [95% CI, -2.80 to 1.09]). Compared with placebo alone, there was no between-group difference in the Bayley-III Cognitive Scale composite score for malaria chemoprevention alone (MD, 1.62 [95% CI, -0.31 to 3.55]). Although the 2 iron interventions increased ferritin concentration, neither reduced anemia prevalence compared with malaria chemoprevention alone. Compared with malaria chemoprevention alone, neither iron syrup and malaria chemoprevention nor iron-containing micronutrient powders and malaria chemoprevention increased malaria risk. Compared with placebo alone, malaria chemoprevention alone reduced the incidence of malaria. CONCLUSIONS AND RELEVANCE: Two universal, 6-month iron interventions with malaria chemoprevention did not improve cognitive outcomes among children in Malawi. TRIAL REGISTRATION: anzctr.org.au Identifier: ACTRN12620000386932.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Phiri KS, Mzembe G, Vokhiwa M, et al. Iron or Multiple Micronutrient Powder Supplements With Malaria Chemoprevention in Rural Malawian Children: The IRMA Randomized Clinical Trial. JAMA. 2026. PMID: 42560689. doi:10.1001/jama.2026.12242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。